Edwards Lifesciences Corporation
Edwards Lifesciences Corporation (EW)
Overview
Edwards Lifesciences is a medical technology company based in Irvine, California, that specializes in devices and technologies for treating advanced structural heart disease, particularly heart valve disorders. Founded in 1958 by engineer Miles "Lowell" Edwards — whose collaboration with Dr. Albert Starr produced the first commercially successful artificial heart valve in 1960 — the company was owned by Baxter International from 1985 until it was spun off as an independent public company in 2000. Edwards employs approximately 16,000 people worldwide and generated roughly $6.1 billion in revenue in fiscal 2025 (up about 11.5% from 2024), following the June 2024 sale of its Critical Care monitoring unit to Becton Dickinson for $4.2 billion, a move that sharpened the company's focus entirely on structural heart disease.
What They Do & How They Make Money
Edwards Lifesciences makes money by designing, manufacturing, and selling implantable heart valves and related delivery systems and repair devices to hospitals and cardiac surgery/cardiology centers, primarily for treating patients with diseased or malfunctioning heart valves (most commonly aortic stenosis, but increasingly mitral and tricuspid valve disease as well). Its flagship product line, the SAPIEN family of transcatheter heart valves, is implanted via a minimally invasive catheter-based procedure (TAVR, transcatheter aortic valve replacement) rather than traditional open-heart surgery, allowing treatment of many patients — including older, higher-risk, and increasingly lower-risk patients — who previously had few good options. Edwards earns revenue primarily from the sale of these valve devices and companion delivery catheters, which historically carry premium, high-margin pricing given their clinical differentiation, extensive supporting clinical trial data, and the specialized regulatory approval required to bring a new valve to market. The company also sells traditional surgical tissue heart valves (used in open-heart procedures) built on its proprietary RESILIA anti-calcification tissue technology, and has been expanding into transcatheter treatments for the mitral and tricuspid valves — a large, historically underserved population — through products like PASCAL and the EVOQUE tricuspid valve. Growth is driven by expanding the eligible patient population (through new FDA indication approvals), international expansion, and continued innovation in newer, less-penetrated valve categories.
Business Segments
Edwards Lifesciences reports results across three main product groups:
- Transcatheter Aortic Valve Replacement (TAVR) — the SAPIEN valve platform for minimally invasive aortic valve replacement; by far the company's largest segment, generating roughly $4.5-4.8 billion in the most recent trailing twelve months (about 73% of total revenue).
- Transcatheter Mitral and Tricuspid Therapies (TMTT) — newer transcatheter devices (PASCAL repair system, EVOQUE tricuspid replacement valve) treating mitral and tricuspid valve disease; the company's fastest-growing segment, having grown from roughly $116 million in 2022 to over $670 million in trailing-twelve-month revenue as adoption ramps.
- Surgical Structural Heart — traditional surgical tissue valves (INSPIRIS RESILIA, MITRIS RESILIA, KONECT RESILIA conduits) used in open-heart procedures; a mature, slower-growing segment generating just over $1 billion annually.
Edwards has bolstered these segments with recent bolt-on acquisitions (Innovalve Bio Medical, JenaValve, Endotronix, and JC Medical in 2024) and continued FDA approvals — including the EVOQUE tricuspid valve (first approved transcatheter tricuspid therapy in the US, February 2024), an implantable heart failure sensor (Cordella, June 2024), and the SAPIEN M3 mitral valve (January 2026) — extending its structural heart franchise into new anatomies and disease states.
Competitors
- TAVR / transcatheter aortic valves: Medtronic (CoreValve/Evolut platform) is Edwards' largest and most direct rival; Abbott (via its Portico/Navitor valve, from the St. Jude Medical acquisition) and Boston Scientific (ACURATE platform) are also active, though Edwards and Medtronic together have historically controlled the large majority of the global TAVR market.
- Mitral/tricuspid transcatheter therapies: Abbott's MitraClip is the dominant incumbent in mitral valve repair, competing against Edwards' PASCAL system; Abbott and Medtronic are also developing competing tricuspid valve technologies against Edwards' EVOQUE.
- Surgical heart valves: Medtronic and Abbott again compete in traditional surgical tissue and mechanical valves, alongside smaller specialty players like LivaNova and Artivion.
Competitive Position
Edwards Lifesciences holds a leadership position in structural heart disease built on decades of clinical evidence, first-mover advantage in TAVR (its SAPIEN valve was the first FDA-approved transcatheter aortic valve, in 2011), and a track record exceeding one million patients treated worldwide with SAPIEN valves — a durability and safety data set that is difficult for competitors to match and that carries significant weight with cardiologists and regulators. The company's focus strategy — sharpened by divesting its non-cardiac Critical Care business in 2024 — concentrates R&D and commercial resources entirely on structural heart disease, an area with large under-penetrated markets (particularly mitral and tricuspid disease, where TMTT is still in the early stages of adoption relative to TAVR's maturity). High regulatory barriers to entry (multi-year clinical trials for each new indication and device generation), strong physician relationships and training investments, and continuous incremental product innovation all support Edwards' moat. Key risks include intensifying competition from Medtronic and Abbott in adjacent categories, pricing and reimbursement pressure as more devices reach the market and hospital systems negotiate harder, execution risk in scaling the newer and clinically more complex TMTT franchise, product recalls or safety signals (a persistent risk in implantable cardiac devices), and reliance on continued favorable clinical trial outcomes and regulatory approvals to expand into new patient populations and geographies.